Abstract
Intracranial microdialysis was utilized to assess the effects of the novel neurotensin antagonist SR 48692 on extracellular gamma-amino-butyric acid (GABA) and glycine in the striatum. Subcutaneous injection of SR 48692 (0.2 mg/kg) significantly decreased extracellular striatal GABA levels, with peak decreases occurring 2-3 h post-injection. Injection of SR 48692 had no significant effect on glycine levels. These data suggest that endogenous neurotensin may modulate striatal GABA levels.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Analysis of Variance
-
Animals
-
Corpus Striatum / drug effects*
-
Corpus Striatum / metabolism
-
Female
-
Glycine / metabolism
-
Injections, Subcutaneous
-
Microdialysis
-
Pyrazoles / pharmacology*
-
Quinolines / pharmacology*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Neurotensin / antagonists & inhibitors*
-
gamma-Aminobutyric Acid / metabolism*
Substances
-
Pyrazoles
-
Quinolines
-
Receptors, Neurotensin
-
SR 48692
-
gamma-Aminobutyric Acid
-
Glycine